Can a simple questionnaire spot depression in new dads? a french study puts it to the test.
NCT ID NCT06594263
First seen Jul 30, 2026 · Last updated Jul 31, 2026 · Updated 1 time
Summary
This study aims to adapt and validate a French version of the PAPA questionnaire, a tool designed to screen for psychological distress in fathers during the perinatal period. Researchers will test the questionnaire with 343 couples to see if it accurately captures symptoms like anxiety and depression that may differ from those in mothers. If validated, the French-PAPA could help healthcare providers better support new fathers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could provide a simple, validated tool for French-speaking clinicians to detect mental health issues in new fathers.
- What could go wrong
- This is a validation study, not a treatment trial. The questionnaire may not capture all aspects of paternal mental health or may not be widely adopted.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AFFECTIVE DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU Clermont-Ferrand
Clermont-Ferrand, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a 9-Week online program lift depression in new dads?
- Text message screening could catch perinatal depression early
- App to prevent postpartum depression tested on 3,000 women
- Virtual forest therapy could soothe pregnancy anxiety
- AI could spot mental health struggles in new moms before they worsen
- Gym workouts boost recovery in young adults on antipsychotics